NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Low Lung Cancer Screening Rates in the US and Recent Progress
TL;DR
Early lung cancer screening provides a survival advantage with 5-year rates reaching 26.6%, giving proactive individuals better health outcomes than those who delay testing.
The American Lung Association reports low screening rates despite lung cancer causing 20% of US cancer deaths, while survival improved from 2015-2019 through advanced treatments.
Increased lung cancer screening and novel treatments from companies like Calidi Biotherapeutics can save lives and reduce the burden of this deadly disease on families.
Lung cancer survival rates have climbed to 26.6% over five years thanks to medical advances, yet most eligible Americans miss early detection opportunities.
Found this article helpful?
Share it with your network and spread the knowledge!
The report shows that only a tiny fraction of Americans eligible for lung cancer screening actually undergo the needed screening.
Lung cancer accounts for 20% of all cancer deaths in America, making early detection through screening critically important for reducing mortality.
Survival rates for lung cancer have increased, with 26.6% of patients now surviving beyond 5 years after treatment, representing an improvement from 2015 to 2019.
Advances in research and novel treatments have been critical in achieving these improved survival results.
The improvement in survival rates occurred during the years 2015 to 2019.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is mentioned as a company focused on building on these advances in lung cancer treatment.
The article was published by BioMedWire, a specialized communications platform focusing on Biotechnology, Biomedical Sciences, and Life Sciences sectors.
Readers can visit https://www.BioMedWire.com for more information about BioMedWire and their services.
To receive SMS alerts from BioMedWire, text 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only).
Curated from InvestorBrandNetwork (IBN)
